Doing now what patients need next!
Read our community guidelines: https://go.roche.com/CG
Read our community guidelines: https://go.roche.com/CG
Location: Switzerland
Employees: 10001+
Total raised: $5.06B
Founded date: 1896
Investors 4
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Sofinnova ... | sofinnova.... |
| - | Lightstone... | lightstone... |
| - | Easton Cap... | eastoncapi... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.08.2021 | - | $5B | - |
| 15.10.2012 | Series D | $24.5M | - |
| 08.03.2012 | Series D | $21.5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent board member |
| 04.11.2021 | Roche Holding AG announces an Equity Buyback for 53,300,000 shares, for CHF 19,000 million. | Roche Holding AG (SWX:ROG) announces a share repurchase program. Under the program, the company will repurchase up to 53,300,000 shares for CHF 19,000 million. The shares will be repurchased at a price of CHF 356.93 per share. These shares ... |
| 15.11.2019 | Roche to Acquire Promedior | Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG;OTCQX: RHHBY) to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior’s entire portfolio of mole... |
| 15.11.2019 | Roche to Acquire Promedior | Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG;OTCQX: RHHBY) to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior’s entire portfolio of mole... |
| 15.10.2012 | Promedior Expands Series D Round to $24.5M | MALVERN, PA, Clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that it has completed a $24.5 million Series D financing round. >> Click here for more funding ... |
| 15.10.2012 | Biotech startup can expand scope of lead fibrotic disease treatment thanks to new funding | The company is also accelerating the development of its drug candidate for fibrovascular retinal diseases such as age-related macular degeneration — a diseases that leads to blindness. It currently affects an estimated 1.75 million people i... |
| 15.10.2012 | Promedior Adds $3M in Series D Financing | Promedior, Inc., a Malvern, PA-based clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, has adding $3m in a second closing of its $24.5m Series D financing. The provider of the funding... |
| 13.03.2012 | Promedior Secures $21.5M Series D | MALVERN, PA, Clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, recently announced that it has raised $21.5M in a first closing of a Series D financing round. >... |
| 08.03.2012 | Promedior Secures $21.5M Series D | MALVERN, PA, Clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, raised $21.5 million in a first closing of a Series D financing round. The financing was led by a n... |
| 08.03.2012 | Promedior Raises $21.5M in Series D Financing | Promedior, Inc., a Malvern, PA-based clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, has raised $21.5m in a first closing of a Series D financing. The round was l... |
Show more